



Coding Systemic Therapy



Lung Cancer Systemic Therapy



Non-Small Cell Lung Cancer

Chemotherapy	Subcategory
Abraxane (Protein-bound Paclitaxel)	Taxane
Afinitor (Everolimus)	Cytostatic agent--antiangiogenesis agent and mTOR inhibitor
Alectinib (Alecensa)	ALK Inhibitor
Brigatinib (Alunbrig)	Anaplastic lymphoma kinase
Carboplatin (Paraplatin)	Alkylating agent , Platinum analog
Ceritinib (Zykadia)	ALK tyrosine kinase inhibitor
Crizotinib (Xalkori)	Kinase inhibitor, Target-ed therapy anaplastic lymphoma kinase
Erlotinib (Tarceva, Erlotinib Hydrochloride)	Cytostatic agent--tyrosine kinase inhibitor, EGF inhibitor
Docetaxel (Taxotere)	Taxane
Gefitinib (Iressa)	Cytostatic agent--tyrosine kinase inhibitor
Gilotrif (Afatinib)	Tyrosine kinase inhibitor
Gemcitabine (Gemzar)	Antimetabolite
Irinotecan (Camptosar)	Topoisomerase inhibitor
Mechlorethamine (Mustargen, Nitrogen Mustard)	Alkylating agent
Methotrexate (Folex, Mexate)	Antimetabolite
Paclitaxel (Taxol)	Mitotic inhibitor, plant alkaloid, Taxane
Pemetrexed (Alimta)	Antimetabolite
Tagrisso (Osimertinib)	EGFR-TKI inhibitor
Vinorelbine (Navelbine)	Plant alkyloid

Adapted from the presentation "Coding Systemic Treatment" and used with permission of Mary B. Davidson, RN, BSN, MN, CTR



Coding Systemic Therapy



Lung Cancer Systemic Therapy



Small Cell Lung Cancer

Chemotherapy Only	Subcategory
Afinitor (Everolimus)	Cytostatic agent--antiangiogenesis agent and mTOR inhibitor
Doxorubicin (Adriamycin)	Antitumor antibiotic
Etoposide (Eposine, Etopophos)	Epipodophyllotoxin, topoisomerase II inhibitor, Plant alkaloid
Irinotecan (Camptosar) + Cisplatin or Carboplatin	Topoisomerase inhibitor
Mechlorethamine (Mustargen, Nitrogen Mustard)	Alkylating agent
Methotrexate (Folex, Mexate)	Antimetabolite
Topotecan (Hycamtin)	Topoisomerase inhibitor

Biological Response Modifiers	Subcategory
Atezolizumab* (Tecentriq, MPDL3208A)	Monoclonal antibody
Bevacizumab (Avastin)	Cytostatic agent--antiangiogenesis agent, Recombinant human anti-VEGF, Vascular endothelial growth factor receptor inhibitor
Cyramza (Ramucirumab)	Antiangiogenesis, Monoclonal antibody
Durvalumab* (Imfinzi) FDA approved 2/18	None
Keytruda (Pembrolizumab) approved 10/18	Monoclonal antibody
Necitumumab (Portrazza)	Anti-EFRG monoclonal antibody
Nivolumab* (Opdivo)	braf inhibitor

* PD-L1 inhibitors: interacts with the
PD-1 protein on T cells

Common drug combinations

Carboplatin & Taxol

Gemzar & Cisplatin

Adapted from the presentation "Coding Systemic Treatment" and used with permission of Mary B. Davidson, RN, BSN, MN, CTR